A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesRelapsed/Refractory AML
Interventions
DRUG

Bexmarilimab

Intravenous

DRUG

Azacitidine

As per label, subcutaneous

DRUG

Venetoclax

Oral

Trial Locations (10)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33520

Tampere University Hospital, Tampere

70210

Kuopio University Hospital, Kuopio

77030

University of Texas, MD Anderson Cancer Center, Houston

90029

Oulu University Hospital, Oulu

91010

City of Hope National Medical Center, Duarte

06510

Yale Cancer Center, New Haven

00029

Helsinki University Hospital, Helsinki

Unknown

The Christie NHS Foundation Trust, Manchester

Royal Cornwall Hospitals NHS Trust, Truro

Sponsors
All Listed Sponsors
lead

Faron Pharmaceuticals Ltd

INDUSTRY

NCT05428969 - A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | Biotech Hunter | Biotech Hunter